A previous work has shown that high numbers of MUC-1pos/EpCAMpos CTCs correlate with shorter overall survival in patients with pancreatic cancer [32], and data suggest that MUC-1 and EpCAM might identify different subtypes of CTCs in pancreatic [33], but also in ovarian [34,35] and metastatic breast cancer [36]. Here, MUC1 is linked to pancreatic neoplasm.